10-QFiled 5 Nov 2026Biotech
REGENXBIO Inc.RGNX
Quarterly report (10-Q), period ending 30 Sep 2026
The shares became cheaper on AIR's value read.
Progress is running ahead of attention.
The price trend strengthened.
The nightly ledger
Every 8-K, 10-Q and 10-K that AIR's companies filed on SEC EDGAR, and what each one changed in AIR's read. Material filings first, newest first — never ordered by price. For 8-K filing alerts, follow a company and turn on filing emails.
By event type: Acquisitions · Major contracts
Seven-day window, 2 weeks back · Material filings: 1629 · All filings: 1839
Thursday 5 Nov642 filings read · 590 material
10-QFiled 5 Nov 2026Biotech
REGENXBIO Inc.RGNX
Quarterly report (10-Q), period ending 30 Sep 2026
The shares became cheaper on AIR's value read.
Progress is running ahead of attention.
The price trend strengthened.
10-QFiled 5 Nov 2026All industries
Graham CorpGHM
Quarterly report (10-Q), period ending 30 Sep 2026
More of the market is starting to notice.
The shares became cheaper on AIR's value read.
Progress is running ahead of attention.
The price trend strengthened.
8-KFiled 5 Nov 2026Biotech
8-K · Item 2.02 — Results of operations
Q3 2026: Revenue $389.9M (+1.5% YoY), adjusted EPS $1.68 (+32.3% YoY). FDA approved TAUKLARIFY and BRAVNETSA. Pending $8B Curium merger at $102.50/share plus up to $12/share CVRs.
Market attention has faded.
8-KFiled 5 Nov 2026Software / SaaS
Cars.com Inc.CARS
8-K · Item 2.02 — Results of operations
Cars.com reported Q3 2026 net income up 113% YoY to $16.3M on flat revenue of $181.9M. Adjusted EBITDA margin of 30.7% exceeded guidance by 120 bps. Marketplace revenue grew 5% YoY; Premium+ adoption reached 12%. Company reaffirmed full-year guidance.
More of the market is starting to notice.
Progress is running ahead of attention.
The price trend strengthened.
10-QFiled 5 Nov 2026Biotech
Quarterly report (10-Q), period ending 30 Sep 2026
Market attention has faded.
10-QFiled 5 Nov 2026Industrials
Quarterly report (10-Q), period ending 30 Sep 2026
More of the market is starting to notice.
Progress is running ahead of attention.
The price trend strengthened.
10-QFiled 5 Nov 2026Banks
Ofg BancorpOFG
Quarterly report (10-Q), period ending 30 Sep 2026
The shares became cheaper on AIR's value read.
The price trend weakened.
8-KFiled 5 Nov 2026Biotech
8-K · Item 2.02 — Results of operations
Disc Medicine's Phase 3 APOLLO trial of bitopertin met all primary and secondary endpoints in erythropoietic protoporphyria. NDA resubmission planned by end-2026 with FDA decision anticipated mid-2027. Strong cash position of $683M extended to 2030.
Progress is running ahead of attention.
10-QFiled 5 Nov 2026All industries
Quarterly report (10-Q), period ending 30 Sep 2026
No notable change in AIR's read.
10-QFiled 5 Nov 2026All industries
Quarterly report (10-Q), period ending 30 Sep 2026
No notable change in AIR's read.
8-KFiled 5 Nov 2026Biotech
8-K · Item 2.02 — Results of operations
Q3 2026: $80.9M revenues (+13% YoY), $13.2M net income. VEPPANU launch generated $6.6M in initial sales. Full-year guidance raised to $290–295M. R289 Phase 1b ongoing; Phase 2 dose selection expected by end-2026.
Market attention has faded.
Progress is running ahead of attention.
The price trend weakened.
10-QFiled 5 Nov 2026All industries
Quarterly report (10-Q), period ending 30 Sep 2026
Progress is running ahead of attention.
The price trend strengthened.
8-KFiled 5 Nov 2026All industries
Gold.com, Inc.GOLD
8-K · Item 2.02 — Results of operations
Gold.com reported Q1 FY2027 earnings with $0.05 diluted EPS (vs. -$0.04 YoY), $1.6M net income, and $17.4M EBITDA. Gross margin expanded to 2.74% despite 11% revenue decline. Company declared $0.20/share dividend and highlighted acquisition synergies.
No notable change in AIR's read.
10-QFiled 5 Nov 2026Industrials
Mks IncMKSI
Quarterly report (10-Q), period ending 30 Sep 2026
Progress is running ahead of attention.
10-QFiled 5 Nov 2026All industries
Quarterly report (10-Q), period ending 30 Sep 2026
More of the market is starting to notice.
The price trend strengthened.
10-QFiled 5 Nov 2026Banks
Quarterly report (10-Q), period ending 30 Sep 2026
No notable change in AIR's read.
8-KFiled 5 Nov 2026All industries
8-K · Item 2.02 — Results of operations
Q3 2026 earnings per diluted share increased 16.7% YoY to $0.70; adjusted EPS grew 18.5% to $0.77. Revenue up 1.9% to $215.9M; operating income up 8.1%. Full-year 2026 EPS guidance raised to $2.93–$2.97 vs. prior $2.42.
Market attention has faded.
The shares became cheaper on AIR's value read.
Progress is running ahead of attention.
The price trend weakened.
10-QFiled 5 Nov 2026All industries
Quarterly report (10-Q), period ending 10 Oct 2026
Progress is running ahead of attention.
8-KFiled 5 Nov 2026Biotech
Mannkind CorpMNKD
8-K · Item 2.02 — Results of operations
Q3 2026 revenues grew 24% YoY to $101.9M, driven by Furoscix ReadyFlow rapid adoption (75% of shipments) and Afrezza pediatric launch success. Commercial product revenue doubled to $45M. Pipeline advanced with positive Phase 1b nintedanib DPI results.
Progress is running ahead of attention.
10-QFiled 5 Nov 2026All industries
LifeStance Health Group, Inc.LFST
Quarterly report (10-Q), period ending 30 Sep 2026
Progress is running ahead of attention.
10-QFiled 5 Nov 2026All industries
Quarterly report (10-Q), period ending 30 Sep 2026
Progress is running ahead of attention.
8-KFiled 5 Nov 2026Biotech
8-K · Item 2.02 — Results of operations
Zenas reported Q3 2026 results with FDA acceptance of obexelimab BLA (PDUFA May 27, 2027), EMA MAA validation for IgG4-RD, positive Phase 3 INDIGO extension data, and $647.1M cash. Phase 2 SunStone SLE and ZB021 Phase 1 data expected Q4 2026.
Progress is running ahead of attention.
10-QFiled 5 Nov 2026All industries
Quarterly report (10-Q), period ending 30 Sep 2026
Progress is running ahead of attention.
The price trend weakened.
10-QFiled 5 Nov 2026Banks
Quarterly report (10-Q), period ending 30 Sep 2026
No notable change in AIR's read.
10-QFiled 5 Nov 2026Biotech
Quarterly report (10-Q), period ending 30 Sep 2026
Progress is running ahead of attention.
8-KFiled 5 Nov 2026Software / SaaS
IonQ, Inc.IONQ
8-K · Items 2.01, 2.02, 3.02 — Acquisition or disposal of assets
IonQ reported Q3 2026 revenue of $173.8M (336% YoY growth), sixth consecutive record quarter. Raised FY2026 guidance to $505–$515M. Backlog grew to $1.2B. Completed Elisity acquisition for quantum security. Advanced to DARPA Stage C with $300M potential value.
The filings read more positively.
More of the market is starting to notice.
Progress is running ahead of attention.
8-KFiled 5 Nov 2026All industries
8-K · Items 2.02, 8.01 — Results of operations
Market attention has faded.
Progress is running ahead of attention.
The price trend weakened.
8-KFiled 5 Nov 2026Biotech
Sarepta Therapeutics, Inc.SRPT
8-K · Item 2.02 — Results of operations
Q3 2026 revenues of $323.8M in net product sales; non-GAAP operating income of $22.9M; raised full-year revenue guidance by $50M; MAD data expected Q4 2026 for DM1 and FSHD programs; $998.7M cash position supports late-stage development.
Progress is running ahead of attention.
10-QFiled 5 Nov 2026Industrials
Quarterly report (10-Q), period ending 30 Sep 2026
More of the market is starting to notice.
Progress is running ahead of attention.
The price trend strengthened.
10-QFiled 5 Nov 2026Software / SaaS
IonQ, Inc.IONQ
Quarterly report (10-Q), period ending 30 Sep 2026
The filings read more positively.
More of the market is starting to notice.
Progress is running ahead of attention.
10-QFiled 5 Nov 2026Biotech
Intellia Therapeutics, Inc.NTLA
Quarterly report (10-Q), period ending 30 Sep 2026
Progress is running ahead of attention.
The price trend strengthened.
10-QFiled 5 Nov 2026Biotech
Enliven Therapeutics, Inc.ELVN
Quarterly report (10-Q), period ending 30 Sep 2026
More of the market is starting to notice.
Progress is running ahead of attention.
The price trend strengthened.
10-QFiled 5 Nov 2026Software / SaaS
Quarterly report (10-Q), period ending 30 Sep 2026
Progress is running ahead of attention.
10-QFiled 5 Nov 2026All industries
Quarterly report (10-Q), period ending 30 Sep 2026
The shares became cheaper on AIR's value read.
Progress is running ahead of attention.
The price trend weakened.
8-KFiled 5 Nov 2026All industries
American Healthcare REIT, Inc.AHR
8-K · Item 2.02 — Results of operations
AHR reported Q3 2026 results with strong Same-Store NOI growth (13.8% total portfolio, 28.2% SHOP, 15.7% ISHC). Company raised full-year 2026 guidance for NFFO per share ($2.23–$2.26) and Same-Store NOI growth (12.0%–14.0%). Acquired $1.69B in new SHOP assets; improved leverage to 1.9x Net Debt-to-Annualized Adjusted EBITDA.
More of the market is starting to notice.
Progress is running ahead of attention.
The price trend strengthened.
10-QFiled 5 Nov 2026Biotech
Quarterly report (10-Q), period ending 30 Sep 2026
Market attention has faded.
The shares became dearer on AIR's value read.
Progress is running ahead of attention.
The price trend weakened.
8-KFiled 5 Nov 2026Biotech
8-K · Item 2.02 — Results of operations
Cogent reports Q3 2026 results with three imminent FDA PDUFA action dates for bezuclastinib (GIST Nov 30, NonAdvSM Dec 30, AdvSM Jun 29, 2027). Cash position of $791.1M funds operations into late 2028. Commercial team in place; pipeline expansion ongoing.
The gap narrowed — attention is catching up.
The price trend strengthened.
8-KFiled 5 Nov 2026Biotech
Tectonic Therapeutic, Inc.TECX
8-K · Item 2.01 — Acquisition or disposal of assets
Tectonic reported favorable Phase 1a safety/tolerability/PK results for TX2100, FDA Fast Track designation for HHT, IND clearance for Phase 1b, first patient dosed in ALPINE Phase 2a for TX45 in PH-ILD, and strong cash position ($234.7M) extending runway to Q1 2029.
No notable change in AIR's read.
8-KFiled 5 Nov 2026Biotech
8-K · Item 2.02 — Results of operations
Q3 2026 revenue $32.9M (flat YoY); net loss $2.5M vs. prior profit. FY2026 guidance affirmed at $100.5–$111.0M. F351 NDA under NMPA review; multiple pipeline programs advancing toward clinical initiation in 2027.
No notable change in AIR's read.
10-QFiled 5 Nov 2026Biotech
Tectonic Therapeutic, Inc.TECX
Quarterly report (10-Q), period ending 30 Sep 2026
No notable change in AIR's read.
10-QFiled 5 Nov 2026All industries
Quarterly report (10-Q), period ending 30 Sep 2026
More of the market is starting to notice.
8-KFiled 5 Nov 2026All industries
8-K · Item 1.01 — Material agreement
CVR Energy completed a $490M equity offering to fund the acquisition of St. Paul Park and Mandan refineries from Marathon Petroleum, plus debt redemption. Offering closed November 5, 2026 at $47.55/share.
The filings read more positively.
Progress is running ahead of attention.
The price trend weakened.
8-KFiled 5 Nov 2026Biotech
Lexicon Pharmaceuticals, Inc.LXRX
8-K · Item 2.02 — Results of operations
Lexicon completed enrollment in Phase 3 SONATA-HCM trial (542 patients, exceeding target) with top-line data expected Q1 2027. STENO1 safety data supports ZYNQUISTA NDA resubmission planned Q1 2027. LX9851 Phase 1 ongoing; Lexicon earned $75M of $1B potential milestones from Novo collaboration.
No notable change in AIR's read.
8-KFiled 5 Nov 2026Industrials
Kratos Defense & Security Solutions, Inc.KTOS
8-K · Item 2.02 — Results of operations
Kratos reported Q3 2026 revenues of $471.8M (35.7% growth, 23.2% organic), bookings of $1.037B (2.2:1 book-to-bill), record backlog of $2.65B, and Adjusted EBITDA of $50.9M (10.8% margin). Raised FY2026 guidance and provided FY2027 forecast of $2.1–$2.2B revenue and $230–$240M Adjusted EBITDA.
The shares became cheaper on AIR's value read.
Progress is running ahead of attention.
The price trend weakened.
10-QFiled 5 Nov 2026All industries
International Seaways, Inc.INSW
Quarterly report (10-Q), period ending 30 Sep 2026
The filings read more positively.
Market attention has faded.
Progress is running ahead of attention.
The price trend weakened.
8-KFiled 5 Nov 2026Software / SaaS
8-K · Item 2.02 — Results of operations
NetScout reported Q2 FY2027 revenue of $222.2M (+1.4% YoY), with operating margin expansion and reaffirmed full-year guidance of $885–$915M revenue. Service revenue grew 6.4%; product backlog declined. Company repurchased $77M in stock.
Market attention has faded.
The shares became cheaper on AIR's value read.
Progress is running ahead of attention.
The price trend weakened.
10-QFiled 5 Nov 2026Software / SaaS
Quarterly report (10-Q), period ending 30 Sep 2026
Market attention has faded.
The shares became cheaper on AIR's value read.
Progress is running ahead of attention.
The price trend weakened.
8-KFiled 5 Nov 2026Biotech
8-K · Item 2.02 — Results of operations
Q3 2026 revenue grew 24.3% YoY to $169.8M; gross profit surged 62.1%. Adjusted EBITDA turned positive at $3.4M (vs. $(3.5)M prior year), exceeding Q3 guidance. Company affirmed full-year 2026 guidance with improved Adjusted EBITDA range ($4–6M vs. $2–7M prior).
Market attention has faded.
The price trend weakened.
10-QFiled 5 Nov 2026Industrials
Quarterly report (10-Q), period ending 30 Sep 2026
Market attention has faded.
Progress is running ahead of attention.
The price trend strengthened.
8-KFiled 5 Nov 2026All industries
8-K · Item 2.02 — Results of operations
Q3 2026 revenue $1.122B (+6% YoY), driven by Cloud Infrastructure Services +34% YoY. Company projects 2027 revenue growth of 17–22% YoY and 2028 revenue exceeding $7.0B, supported by $14B in multi-year CIS commitments signed YTD.
The shares became dearer on AIR's value read.
Progress is running ahead of attention.
10-QFiled 5 Nov 2026All industries
Quarterly report (10-Q), period ending 30 Sep 2026
Progress is running ahead of attention.
The price trend strengthened.
10-QFiled 5 Nov 2026All industries
Quarterly report (10-Q), period ending 30 Sep 2026
No notable change in AIR's read.
8-KFiled 5 Nov 2026Industrials
Enovis CORPENOV
8-K · Item 2.02 — Results of operations
Q3 2026: 5% organic sales growth, Reconstructive segment +6%, adjusted EBITDA and EPS guidance raised. Board approved $200M share repurchase authorization. Company executing innovation strategy despite market headwinds.
More of the market is starting to notice.
Progress is running ahead of attention.
The price trend strengthened.
8-KFiled 5 Nov 2026All industries
8-K · Item 2.02 — Results of operations
Q3 2026 net income increased 94% to $3.3M ($0.12/share) vs. $1.7M prior year. Revenues rose 70% to $25.0M. Adjusted EBITDA grew 96% to $10.4M. Corporate expenses fell 39.8%. All segments showed improvement.
Progress is running ahead of attention.
The price trend strengthened.
8-KFiled 5 Nov 2026Industrials
8-K · Item 2.02 — Results of operations
LSI reported Q1 FY2027 net sales of $225.9M (+44% YoY), adjusted net income of $11.6M (+$0.31 EPS), and free cash flow of $13.8M. Organic sales declined 2% excluding Royston acquisition. Key wins include 2,500-site refueling refresh and 3,000-store QSR renovation program.
Progress is running ahead of attention.
The price trend weakened.
10-QFiled 5 Nov 2026Biotech
Palvella Therapeutics, Inc.PVLA
Quarterly report (10-Q), period ending 30 Sep 2026
More of the market is starting to notice.
Progress is running ahead of attention.
The price trend strengthened.
8-KFiled 5 Nov 2026Biotech
8-K · Item 2.02 — Results of operations
Pulse Biosciences completed enrollment of NANOPULSE-AF pivotal study three months ahead of schedule with 169 patients. Company raised $95.8M in Q3 via ATM, ending quarter with $189.2M cash. Vybrance revenue grew to $0.4M; PRECISE-BTN study fully enrolled.
No notable change in AIR's read.
10-QFiled 5 Nov 2026Biotech
Quarterly report (10-Q), period ending 30 Sep 2026
No notable change in AIR's read.
10-QFiled 5 Nov 2026Semiconductors
Applied Optoelectronics, Inc.AAOI
Quarterly report (10-Q), period ending 30 Sep 2026
Market attention has faded.
The shares became cheaper on AIR's value read.
Progress is running ahead of attention.
10-QFiled 5 Nov 2026Biotech
Iovance Biotherapeutics, Inc.IOVA
Quarterly report (10-Q), period ending 30 Sep 2026
The shares became cheaper on AIR's value read.
Progress is running ahead of attention.
The price trend weakened.
8-KFiled 5 Nov 2026Software / SaaS
8-K · Item 2.02 — Results of operations
PDF Solutions reported Q3 2026 record revenues of $68.3M (+20% YoY), with GAAP gross margin of 73% and operating margin of 12%. GAAP diluted EPS of $0.16 vs. $0.03 prior year. Company reaffirmed 20% annual revenue growth target for 2026.
Market attention has faded.
The shares became cheaper on AIR's value read.
8-KFiled 5 Nov 2026Industrials
8-K · Item 2.02 — Results of operations
Q3 2026 sales grew 14% YoY to $283.7M; gross margin expanded 270bps to 57%; operating loss improved 830bps to -1% of sales. Adjusted EBITDA reached $18.0M (6% margin) vs. $2.8M prior year. Pharmacy channel now 15% of U.S. sales; international expansion accelerating.
Progress is running ahead of attention.
The price trend strengthened.
10-QFiled 5 Nov 2026Industrials
Quarterly report (10-Q), period ending 30 Sep 2026
Progress is running ahead of attention.
The price trend strengthened.
8-KFiled 5 Nov 2026Software / SaaS
Appian CorpAPPN
8-K · Item 2.02 — Results of operations
Q3 2026 revenue grew 25% YoY to $234.6M; cloud subscriptions revenue up 20% to $136.4M. GAAP net income $12.3M vs $7.8M prior year. Full-year 2026 guidance raised with cloud subscriptions expected at $536–$538M (23% growth).
Progress is running ahead of attention.
10-QFiled 5 Nov 2026Software / SaaS
Appian CorpAPPN
Quarterly report (10-Q), period ending 30 Sep 2026
Progress is running ahead of attention.
10-QFiled 5 Nov 2026Semiconductors
SITIME CorpSITM
Quarterly report (10-Q), period ending 30 Sep 2026
Progress is running ahead of attention.
The price trend weakened.
8-KFiled 5 Nov 2026Software / SaaS
8-K · Item 2.02 — Results of operations
Q3 2026 SaaS revenue grew 9.0% to $191.2M; GAAP net income $34.3M; non-GAAP adjusted EBITDA $66.2M (+19.2% YoY). Company raised full-year 2026 SaaS guidance by $12.2M midpoint and increased adjusted EBITDA outlook. CellGate acquisition and new AI video features announced.
The shares became cheaper on AIR's value read.
Progress is running ahead of attention.
10-QFiled 5 Nov 2026Industrials
Quarterly report (10-Q), period ending 30 Sep 2026
More of the market is starting to notice.
Progress is running ahead of attention.
The price trend strengthened.
8-KFiled 5 Nov 2026All industries
HA Sustainable Infrastructure Capital, Inc.HASI
8-K · Item 2.02 — Results of operations
HASI reported Q3 2026 Adjusted EPS of $0.82 vs. $0.80 YoY, with YTD Adjusted EPS growth of 15%. Adjusted Recurring Net Investment Income grew 15% YoY to $121M. Managed Assets reached $19.0B (+27% YoY). New investment yields exceed 11%. Reaffirmed 2028 guidance.
No notable change in AIR's read.
10-QFiled 5 Nov 2026All industries
SiriusPoint LtdSPNT
Quarterly report (10-Q), period ending 30 Sep 2026
More of the market is starting to notice.
Progress is running ahead of attention.
10-QFiled 5 Nov 2026All industries
Corvel CorpCRVL
Quarterly report (10-Q), period ending 30 Sep 2026
The shares became cheaper on AIR's value read.
Progress is running ahead of attention.
The price trend weakened.
8-KFiled 5 Nov 2026All industries
SiriusPoint LtdSPNT
8-K · Items 2.02, 8.01 — Results of operations
Q3 2026 net income of $87M ($0.74 EPS) with 19% operating EPS growth. Core combined ratio 90.1%, ROE 15.4%. Loss portfolio transfer with RiverStone expected to unlock $200M+ capital from run-off reserves.
More of the market is starting to notice.
Progress is running ahead of attention.
10-QFiled 5 Nov 2026All industries
Celcuity Inc.CELC
Quarterly report (10-Q), period ending 30 Sep 2026
No notable change in AIR's read.
10-QFiled 5 Nov 2026Banks
Hyperliquid Strategies IncPURR
Quarterly report (10-Q), period ending 30 Sep 2026
Market attention has faded.
The price trend weakened.
8-KFiled 5 Nov 2026Software / SaaS
8-K · Item 2.02 — Results of operations
Q1 FY2027 recurring revenue grew 12.0% YoY to $424.5M; total revenue up 10.7% to $451.7M. Net income $57.6M ($1.07/share) vs. $48.0M ($0.86/share) prior year. Company raised full-year FY2027 guidance. Aidora acquisition completed; $152.5M share repurchase executed.
Progress is running ahead of attention.
The price trend strengthened.
10-QFiled 5 Nov 2026All industries
Quarterly report (10-Q), period ending 30 Sep 2026
Market attention has faded.
The price trend weakened.
8-KFiled 5 Nov 2026All industries
8-K · Item 2.02 — Results of operations
Dorian LPG reported Q2 FY2027 net income of $213.9M ($4.98 EPS), up 286% YoY, driven by elevated TCE rates ($96,990/day, +80.5% YoY), vessel sales gains ($63.6M), and strong revenues ($221.3M, +78.4% YoY). Declared $1.25/share dividend.
Market attention has faded.
The price trend weakened.
8-KFiled 5 Nov 2026All industries
Advanced Drainage Systems, Inc.WMS
8-K · Items 2.02, 8.01 — Results of operations
Q2 FY2027: Net sales +4.6% to $889.4M; Adjusted EBITDA $286.8M (32.2% margin). YTD organic sales +2.3%, Adjusted EBITDA +14.0%. Announced StormTrap acquisition. Dividend increased to $0.20/share. Guidance updated; demand softer than expected.
Progress is running ahead of attention.
The price trend weakened.
10-QFiled 5 Nov 2026Software / SaaS
Procore Technologies, Inc.PCOR
Quarterly report (10-Q), period ending 30 Sep 2026
The gap narrowed — attention is catching up.
The price trend strengthened.
10-QFiled 5 Nov 2026Software / SaaS
Nerdwallet, Inc.NRDS
Quarterly report (10-Q), period ending 30 Sep 2026
No notable change in AIR's read.
8-KFiled 5 Nov 2026Software / SaaS
Nerdwallet, Inc.NRDS
8-K · Item 2.02 — Results of operations
Q3 2026 revenue grew 11% YoY to $239.6M, but operating income fell 44% YoY to $19.4M and net income declined 43% YoY to $14.9M. Non-GAAP operating income and adjusted EBITDA also declined significantly YoY.
No notable change in AIR's read.
8-KFiled 5 Nov 2026All industries
HF Sinclair CorpDINO
8-K · Item 1.01 — Material agreement
HF Sinclair repurchased 2.1M shares from REH Advisors at $110.81/share (~$233M) under its $1.5B authorization. This is the 24th transaction with REH; $1B deployed to date, ~$493M remaining.
Market attention has faded.
The shares became cheaper on AIR's value read.
The price trend weakened.
10-QFiled 5 Nov 2026All industries
Quarterly report (10-Q), period ending 30 Sep 2026
No notable change in AIR's read.
10-QFiled 5 Nov 2026Semiconductors
Quarterly report (10-Q), period ending 30 Sep 2026
The shares became cheaper on AIR's value read.
Progress is running ahead of attention.
The price trend weakened.
8-KFiled 5 Nov 2026Industrials
8-K · Item 2.02 — Results of operations
Ducommun reported Q3 2026 record revenue of $227.0M (+6% YoY) and record gross margin of 28.9% (+140 bps). Net income $13.9M vs. prior-year loss of $60.8M. RPO at all-time high of $1.3B; defense book-to-bill 2.2x.
Market attention has faded.
The price trend weakened.
8-KFiled 5 Nov 2026All industries
Ingredion IncINGR
8-K · Item 2.02 — Results of operations
The shares became cheaper on AIR's value read.
10-QFiled 5 Nov 2026Industrials
Quarterly report (10-Q), period ending 3 Oct 2026
Market attention has faded.
The price trend weakened.
10-QFiled 5 Nov 2026All industries
Scansource, Inc.SCSC
Quarterly report (10-Q), period ending 30 Sep 2026
The reported numbers improved.
Market attention has faded.
The gap closed as the filings read less positively.
The price trend weakened.
8-KFiled 5 Nov 2026All industries
8-K · Item 2.02 — Results of operations
Americold reported Q3 2026 results with 4.2% YoY revenue growth, 6.0% same-store NOI growth, and maintained Adjusted FFO of $0.35/share. Company raised full-year AFFO guidance to $1.31–$1.33/share and reduced debt by $1.15B via EQT joint venture closing, improving net leverage by one turn.
Progress is running ahead of attention.
The price trend strengthened.
10-QFiled 5 Nov 2026All industries
Quarterly report (10-Q), period ending 30 Sep 2026
The shares became dearer on AIR's value read.
The gap narrowed — attention is catching up.
The price trend strengthened.
8-KFiled 5 Nov 2026Industrials
Vontier CorpVNT
8-K · Item 2.02 — Results of operations
Q3 2026 results exceeded guidance with adjusted EPS of $0.92 and 12.1% adjusted operating profit growth. Company raised full-year adjusted EPS guidance to $3.60–$3.64. Core sales grew 5.7% despite 2.1% reported sales decline due to divestiture.
More of the market is starting to notice.
Progress is running ahead of attention.
The price trend strengthened.
8-KFiled 5 Nov 2026All industries
Papa Johns International IncPZZA
8-K · Item 2.02 — Results of operations
Q3 2026 results show significant declines: global system-wide sales down 5.6%, North America comparable sales down 8.3%, net income down 27%, adjusted EBITDA down 20%. Company lowered full-year guidance materially across key metrics.
The shares became dearer on AIR's value read.
The price trend strengthened.
10-QFiled 5 Nov 2026All industries
Papa Johns International IncPZZA
Quarterly report (10-Q), period ending 27 Sep 2026
The shares became dearer on AIR's value read.
The price trend strengthened.
8-KFiled 5 Nov 2026Banks
GPGI, Inc.GPGI
8-K · Items 2.02, 8.01 — Results of operations
GPGI lowered FY26 Adjusted EBITDA guidance by ~$45M (~8%) and Adjusted Free Cash Flow by ~$25M (~8%) due to Husky margin headwinds from delayed cost actions, freight costs, and mix, despite maintaining prior sales forecast and declaring quarterly dividend.
The gap narrowed — attention is catching up.
The price trend strengthened.
8-KFiled 5 Nov 2026All industries
BKV CorpBKV
8-K · Item 2.02 — Results of operations
Q3 2026: BKV reported net income of $29.4M ($0.27/share), adjusted net income of $39.9M ($0.36/share), and adjusted EBITDAX of $132.7M. Key wins include cost reimbursement agreement expanding Temple modular power from 200MW to 400MW, backstop agreement with investment-grade hyperscaler for 1.2GW CCGT equipment, and Verra carbon credit certification enabling CSG monetization.
No notable change in AIR's read.
8-KFiled 5 Nov 2026All industries
Installed Building Products, Inc.IBP
8-K · Item 2.02 — Results of operations
Q3 2026 revenue grew 3.9% to record $808.4M, but net income fell 20% YoY to $59.4M. Adjusted EBITDA declined 8.3% to $128.3M with margin compression from 18.0% to 15.9%, driven by residential weakness, cost inflation in fuel/aluminum, and unfavorable segment mix.
More of the market is starting to notice.
The price trend strengthened.
8-KFiled 5 Nov 2026Software / SaaS
Sabre CorpSABR
8-K · Item 2.02 — Results of operations
Sabre reported Q3 2026 revenue of $738M (+3% YoY), exceeded Adjusted EBITDA guidance, achieved fifth consecutive quarter of double-digit Normalized Adjusted EBITDA growth (+13% YoY to $170M), and raised full-year 2026 Pro Forma Adjusted EBITDA and Free Cash Flow guidance for the second consecutive quarter.
The shares became dearer on AIR's value read.
8-KFiled 5 Nov 2026Biotech
8-K · Item 2.02 — Results of operations
Shattuck Labs initiated Phase 2b trial (RECEPTIVE-CD1) for SL-325 in Crohn's disease with 12-week data expected H1 2028, announced Phase 2 trial (RECEPTIVE-HS1) in hidradenitis suppurativa starting Q4 2026, and presented preclinical data for SL-846 bispecific candidate showing favorable tolerability and blockade profiles.
Market attention has faded.
Progress is running ahead of attention.
10-QFiled 5 Nov 2026Industrials
Imax CorpIMAX
Quarterly report (10-Q), period ending 30 Sep 2026
The shares became cheaper on AIR's value read.
Progress is running ahead of attention.
8-KFiled 5 Nov 2026All industries
Construction Partners, Inc.ROAD
8-K · Item 2.02 — Results of operations
FY2026 preliminary results show ~30% revenue growth to $3.66–3.68B and ~40% net income growth to $141.5–142.5M. FY2027 outlook guides 15% growth at midpoint. Company completed acquisition of Piedmont Paving in Georgia and three additional acquisitions early in FY2027.
Market attention has faded.
The price trend weakened.
Sun 22 Nov
CAPR · Capricor Therapeutics, Inc. · Regulatory date
As stated in the filing: “Deramiocel Biologics License Application (BLA) for Duchenne muscular dystrophy (DMD) under FDA review; PDUFA target action date of November 22, 2026 ●”
Announced by the company in 8-K on 10 Nov 2026
DYN · Dyne Therapeutics, Inc. · Regulatory date
As stated in the filing: “Capricor Therapeutics’ BLA for its cell therapy deramiocel is currently under FDA review with a PDUFA date of November 22, 2026.”
Announced by the company in 10-Q on 5 Nov 2026
SVRA · Savara Inc · Regulatory date
As stated in the filing: “The FDA determined that the Company’s responses to recent information requests by the Agency during its review constituted a major amendment to the BLA, resulting in a three-month extension of the Prescription Drug User Fee Act ("PDUFA") target action date to November 22, 2026.”
Announced by the company in 10-Q on 9 Nov 2026
Fri 27 Nov
BBIO · BridgeBio Pharma, Inc. · Regulatory date
As stated in the filing: “The first participant was dosed in ASCEND-ATTR, the Phase 3b/4 study to prospectively test disease reversal with Attruby - BBP-418 for LGMD2I/R9 has a November 27, 2026 PDUFA date, with Priority Review.”
Announced by the company in 8-K on 29 Oct 2026
Mon 30 Nov
COGT · Cogent Biosciences, Inc. · Regulatory date
As stated in the filing: “Potential FDA approval of bezuclastinib in GIST – PDUFA date of November 30, 2026 •”
Announced by the company in 8-K on 5 Nov 2026
JBIO · Jade Biosciences, Inc. · Regulatory date
As stated in the filing: “The FDA has also accepted a Biologics License Application for accelerated approval of povetacicept in IgAN, with a Prescription Drug User Fee Act target action date of November 30, 2026.”
Announced by the company in 10-Q on 13 Nov 2026
Wed 2 Dec
ARE · Alexandria Real Estate Equities, Inc. · Investor day
As stated in the filing: “We expect to introduce 2027 guidance and related assumptions at our Investor Day on December 2, 2026, consistent with our historical practice.”
Announced by the company in 8-K on 27 Apr 2026
Thu 3 Dec
EXEL · Exelixis, Inc. · Regulatory date
As stated in the filing: “In February 2026, we announced that the FDA had accepted our NDA and assigned a standard review, with a Prescription Drug User Fee Act (PDUFA) target action date of December 3, 2026.”
Announced by the company in 10-Q on 29 Oct 2026
Tue 8 Dec
GPC · Genuine Parts Co · Investor day
As stated in the filing: “In addition, the Company announced that both Global Automotive and Global Industrial will host separate investor days on December 8, 2026 and December 9, 2026, respectively.”
Announced by the company in 8-K on 9 Sep 2026
LGND · Ligand Pharmaceuticals Inc · Investor day
As stated in the filing: “Ligand will provide an updated 5-year outlook during the Company’s Investor Day on December 8, 2026.”
Announced by the company in 8-K on 14 Jul 2026
Wed 9 Dec
GPC · Genuine Parts Co · Investor day
As stated in the filing: “Investor Days GPC and Motion will host separate investor days in New York City, with GPC’s Investor Day scheduled for December 8, 2026, and Motion’s Investor Day scheduled for December 9, 2026.”
Announced by the company in 8-K on 9 Sep 2026
Sat 12 Dec
ANAB · Anaptysbio, Inc · Regulatory date
As stated in the filing: “FDA target action date (PDUFA) of December 12, 2026, for Quimilza in generalized pustular psoriasis (GPP) GSK and Tesaro Litigation Update •”
Announced by the company in 8-K on 12 Nov 2026
Thu 17 Dec
CORT · Corcept Therapeutics Inc · Regulatory date
As stated in the filing: “Relacorilant for patients with Cushing’s syndrome – Resubmitted New Drug Application Prescription Drug User Fee Act (PDUFA) date of December 17, 2026 “The ADA and EASD consensus statement is an important advance for the many patients whose difficult-to-control hyperglycemia is a manifestation of undiagnosed Cushing’s syndrome,” said Bill Guyer, PharmD, Corcept’s Chief Development Officer.”
Announced by the company in 8-K on 3 Nov 2026
Mon 23 Nov
MATW · Matthews International Corp · All industries
Annual results due — last year filed 21 Nov 2025
Last quarter (Q3 2026, against a year earlier): revenue down 30%, net income turned to a loss
AIR's current read: News flow Balanced, Gap Low · 0
Tue 24 Nov
BLBD · Blue Bird Corp · Industrials
Annual results due — last year filed 24 Nov 2025
Last quarter (Q3 2026, against a year earlier): revenue up 30%, net income up 408%
AIR's current read: News flow Balanced, Gap Very high · 82
PFLT · PennantPark Floating Rate Capital Ltd. · All industries
Annual results due — last year filed 24 Nov 2025
AIR's current read: News flow Balanced, Gap Very high · 71
Wed 25 Nov
AMTM · Amentum Holdings, Inc. · All industries
Annual results due — last year filed 25 Nov 2025
Last quarter (Q3 2025, against a year earlier): revenue up 66%, net income turned positive
AIR's current read: News flow Balanced, Gap Low · 4
ARMK · Aramark · All industries
Annual results due — last year filed 25 Nov 2025
Last quarter (Q3 2025, against a year earlier): revenue up 6%, net income up 23%
AIR's current read: News flow Balanced, Gap Medium · 10
CASH · Pathward Financial, Inc. · Banks
Annual results due — last year filed 25 Nov 2025
Last quarter (Q3 2026, against a year earlier): revenue down 3%, net income down 31%
AIR's current read: News flow Balanced, Gap Low · 0
CLSK · Cleanspark, Inc. · Banks
Annual results due — last year filed 25 Nov 2025
Last quarter (Q3 2024, against a year earlier): revenue up 129%, net loss widened
AIR's current read: News flow Balanced, Gap Very high · 54
GAP · Gap Inc · All industries
Quarterly results due — last year filed 25 Nov 2025
Last quarter (Q3 2024, against a year earlier): revenue down 7%, net income down 23%
AIR's current read: News flow Balanced, Gap Low · 3
ROAD · Construction Partners, Inc. · All industries
Annual results due — last year filed 25 Nov 2025
Last quarter (Q3 2026, against a year earlier): revenue up 28%, net income up 35%
AIR's current read: News flow Balanced, Gap Low · 7
SJM · J M SMUCKER Co · All industries
Quarterly results due — last year filed 25 Nov 2025
Last quarter (Q3 2026, against a year earlier): revenue up 7%, net loss widened
AIR's current read: News flow Balanced, Gap Low · 7
SMG · Scotts Miracle-Gro Co · All industries
Annual results due — last year filed 25 Nov 2025
Last quarter (Q3 2026, against a year earlier): revenue up 1%, net income down 25%
AIR's current read: News flow Balanced, Gap Medium · 12
SMTC · Semtech Corp · Semiconductors
Quarterly results due — last year filed 25 Nov 2025
Last quarter (Q1 2027, against a year earlier): revenue up 16%, net income up 37%
AIR's current read: News flow Balanced, Gap Low · 0
TFSL · TFS Financial CORP · Banks
Annual results due — last year filed 25 Nov 2025
Last quarter (Q1 2019, against a year earlier): net income up 4%
AIR's current read: News flow Balanced, Gap Medium · 23
Fri 27 Nov
ATKR · Atkore Inc. · Industrials
Annual results due — last year filed 26 Nov 2025
Last quarter (Q3 2026, against a year earlier): revenue up 8%, net income down 98%
AIR's current read: News flow Balanced, Gap Low · 0
BJ · BJ's Wholesale Club Holdings, Inc. · All industries
Quarterly results due — last year filed 26 Nov 2025
Last quarter (Q2 2027, against a year earlier): revenue up 16%, net income up 15%
AIR's current read: News flow Balanced, Gap Medium · 18
CENT · Central Garden & Pet Co · All industries
Annual results due — last year filed 26 Nov 2025
Last quarter (Q3 2026, against a year earlier): revenue down 8%, net income down 5%
AIR's current read: News flow Balanced, Gap Low · 1
CFFN · Capitol Federal Financial, Inc. · Banks
Annual results due — last year filed 26 Nov 2025
Last quarter (Q3 2020, against a year earlier): net income down 15%
AIR's current read: News flow Balanced, Gap Medium · 10
JJSF · J&J Snack Foods Corp · All industries
Annual results due — last year filed 26 Nov 2025
Last quarter (Q3 2026, against a year earlier): revenue down 6%, net income down 20%
AIR's current read: News flow Balanced, Gap Low · 0
PD · PagerDuty, Inc. · Software / SaaS
Quarterly results due — last year filed 26 Nov 2025
Last quarter (Q1 2027, against a year earlier): revenue up 1%, net income turned positive
AIR's current read: News flow Balanced, Gap Low · 0
SPH · Suburban Propane Partners Lp · All industries
Annual results due — last year filed 26 Nov 2025
Last quarter (Q3 2026, against a year earlier): revenue unchanged, net loss widened
AIR's current read: News flow Balanced, Gap Medium · 21
UTI · Universal Technical Institute Inc · All industries
Annual results due — last year filed 26 Nov 2025
Last quarter (Q3 2026, against a year earlier): revenue up 7%, net income down 79%
AIR's current read: News flow Balanced, Gap Very high · 57
Mon 30 Nov
SNEX · StoneX Group Inc. · All industries
Annual results due — last year filed 28 Nov 2025
Last quarter (Q3 2026, against a year earlier): revenue up 15%, net income up 102%
AIR's current read: News flow Balanced, Gap Very high · 52
Tue 1 Dec
ESE · Esco Technologies Inc · Industrials
Annual results due — last year filed 1 Dec 2025
Last quarter (Q3 2026, against a year earlier): revenue up 14%, net income up 26%
AIR's current read: News flow Balanced, Gap Very high · 97
Wed 2 Dec
ASAN · Asana, Inc. · Software / SaaS
Quarterly results due — last year filed 2 Dec 2025
Last quarter (Q2 2027, against a year earlier): revenue up 10%, net loss narrowed
AIR's current read: News flow Balanced, Gap Low · 0
UNFI · United Natural Foods Inc · All industries
Quarterly results due — last year filed 2 Dec 2025
AIR's current read: News flow Balanced, Gap Low · 0
VSTS · Vestis Corp · All industries
Annual results due — last year filed 2 Dec 2025
Last quarter (Q3 2025, against a year earlier): revenue down 4%, net income turned to a loss
AIR's current read: News flow Balanced, Gap Low · 1
Thu 3 Dec
BOX · Box Inc · Software / SaaS
Quarterly results due — last year filed 3 Dec 2025
Last quarter (Q2 2027, against a year earlier): revenue up 9%, net income up 43%
AIR's current read: News flow Balanced, Gap Low · 1
CRWD · CrowdStrike Holdings, Inc. · Software / SaaS
Quarterly results due — last year filed 3 Dec 2025
Last quarter (Q1 2027, against a year earlier): revenue up 26%, net income turned positive
AIR's current read: News flow Balanced, Gap Low · 5
HQY · Healthequity, Inc. · All industries
Quarterly results due — last year filed 3 Dec 2025
Last quarter (Q2 2027, against a year earlier): revenue up 8%, net income up 10%
AIR's current read: News flow Balanced, Gap Low · 0
KSS · KOHLS Corp · All industries
Quarterly results due — last year filed 3 Dec 2025
Last quarter (Q3 2024, against a year earlier): revenue down 5%, net income down 39%
AIR's current read: News flow Balanced, Gap Medium · 11
MEI · Methode Electronics Inc · Industrials
Quarterly results due — last year filed 3 Dec 2025
AIR's current read: News flow Balanced, Gap Low · 0
NCNO · nCino, Inc. · Software / SaaS
Quarterly results due — last year filed 3 Dec 2025
Last quarter (Q1 2027, against a year earlier): revenue up 11%, net income up 145%
AIR's current read: News flow Balanced, Gap Low · 5
THO · Thor Industries Inc · Industrials
Quarterly results due — last year filed 3 Dec 2025
Last quarter (Q4 2026, against a year earlier): revenue down 8%, net income down 68%
AIR's current read: News flow Balanced, Gap Low · 4
Fri 4 Dec
AGX · Argan Inc · All industries
Quarterly results due — last year filed 4 Dec 2025
Last quarter (Q2 2027, against a year earlier): revenue up 62%, net income up 51%
AIR's current read: News flow Balanced, Gap Low · 9
AMBA · Ambarella Inc · Semiconductors
Quarterly results due — last year filed 4 Dec 2025
Last quarter (Q2 2027, against a year earlier): revenue up 13%, net loss narrowed
AIR's current read: News flow Balanced, Gap Low · 7
BF-B · Brown Forman Corp · All industries
Quarterly results due — last year filed 4 Dec 2025
Last quarter (Q1 2027, against a year earlier): revenue down 1%, net income up 4%
AIR's current read: News flow Balanced, Gap Low · 0
CXM · Sprinklr, Inc. · Software / SaaS
Quarterly results due — last year filed 4 Dec 2025
Last quarter (Q2 2027, against a year earlier): revenue up 1%, net income down 44%
AIR's current read: News flow Balanced, Gap Low · 9
DCI · DONALDSON Co INC · All industries
Quarterly results due — last year filed 4 Dec 2025
Last quarter (Q4 2026, against a year earlier): revenue up 8%, net income up 13%
AIR's current read: News flow Balanced, Gap Low · 9
FIVE · Five Below, Inc · All industries
Quarterly results due — last year filed 4 Dec 2025
Last quarter (Q3 2024, against a year earlier): revenue up 14%, net income down 10%
AIR's current read: News flow Balanced, Gap High · 27
GWRE · Guidewire Software, Inc. · Software / SaaS
Quarterly results due — last year filed 4 Dec 2025
Last quarter (Q3 2026, against a year earlier): revenue up 27%, net income down 64%
AIR's current read: News flow Balanced, Gap High · 44
NTNX · Nutanix, Inc. · Software / SaaS
Quarterly results due — last year filed 4 Dec 2025
Last quarter (Q3 2026, against a year earlier): revenue up 10%, net income up 14%
AIR's current read: News flow Balanced, Gap Medium · 22
REX · REX AMERICAN RESOURCES Corp · All industries
Quarterly results due — last year filed 4 Dec 2025
Last quarter (Q2 2027, against a year earlier): revenue up 6%, net income up 336%
AIR's current read: News flow Balanced, Gap Low · 0
SAIC · Science Applications International Corp · Software / SaaS
Quarterly results due — last year filed 4 Dec 2025
AIR's current read: News flow Balanced, Gap High · 39
SWBI · Smith & Wesson Brands, Inc. · Industrials
Quarterly results due — last year filed 4 Dec 2025
Last quarter (Q1 2027, against a year earlier): revenue up 32%, net income turned positive
AIR's current read: News flow Balanced, Gap Very high · 87
TITN · Titan Machinery Inc. · All industries
Quarterly results due — last year filed 4 Dec 2025
Last quarter (Q2 2027, against a year earlier): revenue down 9%, net loss widened
AIR's current read: News flow Balanced, Gap Low · 0
Expected dates come from each company's filing history. They are not forecasts, and companies move them.
Sign in to follow companies
Follow a company and its filings show up here.
Sign inResearch, not tips. Filings come from SEC EDGAR; AIR's read is recomputed every trading day. A price move is shown as a fact beside a filing, never as the reason it is listed.